Advertisement

Topics

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H1 2015

01:13 EDT 15 Apr 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-02-27. This 91-page report is available in PDF from $2000.

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H1 2015’, provides an overview of the Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and…

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Overview 8
Therapeutics Development 9
Pipeline Products for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Overview 9
Pipeline Products for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Comparative Analysis 10
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Therapeutics under Development by Companies 11
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Products under Development by Companies 15
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Companies Involved in Therapeutics Development 16
Anthera Pharmaceuticals‚ Inc. 16
Azano Pharmaceuticals Inc. 17
Boehringer Ingelheim GmbH 18
Bristol-Myers Squibb Company 19
Eisai Co., Ltd. 20
GlaxoSmithKline plc 21
HanAll Biopharma Co., Ltd. 22
Immunomedics, Inc. 23
Merck & Co., Inc. 24
Momenta Pharmaceuticals, Inc. 25
Pfizer Inc. 26
PhytoHealth Corporation 27
Rigel Pharmaceuticals, Inc. 28
SuppreMol GmbH 29
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Target 31
Assessment by Mechanism of Action 33
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
Antibody for Autoimmune Disorders and Inflammation - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
avatrombopag - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
AZ-175 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
belimumab - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
BI-655064 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
blisibimod - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
BMS-986004 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
eltrombopag olamine - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
fostamatinib disodium - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
GL-2045 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
GSK-2285921 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
HL-161 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
MK-8723 - Drug Profile 60
Product Description 60
Mechanism of Action 60 For more information open Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H1 2015.

SKU: GMDHC6354IDB

Original Article: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H1 2015

NEXT ARTICLE

More From BioPortfolio on "Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H1 2015"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...